Free Trial

Sol-Gel Technologies (SLGL) Competitors

Sol-Gel Technologies logo
$8.16 -0.25 (-2.97%)
Closing price 07/18/2025 03:58 PM Eastern
Extended Trading
$8.06 -0.11 (-1.29%)
As of 07/18/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLGL vs. CHEK, DRCT, EXOZ, CABA, JMAC, IGMS, PLRX, ZURA, EPIX, and QNCX

Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Check-Cap (CHEK), Direct Digital (DRCT), eXoZymes (EXOZ), Cabaletta Bio (CABA), Maxpro Capital Acquisition (JMAC), IGM Biosciences (IGMS), Pliant Therapeutics (PLRX), Zura Bio (ZURA), ESSA Pharma (EPIX), and Quince Therapeutics (QNCX).

Sol-Gel Technologies vs. Its Competitors

Sol-Gel Technologies (NASDAQ:SLGL) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Check-Cap has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -107.78%. Check-Cap's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Sol-Gel Technologies-107.78% -43.98% -35.28%
Check-Cap N/A N/A N/A

Sol-Gel Technologies has higher revenue and earnings than Check-Cap. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sol-Gel Technologies$11.54M1.97-$10.58M-$4.70-1.74
Check-CapN/AN/A-$17.57M-$3.00-0.25

Sol-Gel Technologies has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Sol-Gel Technologies currently has a consensus target price of $40.00, indicating a potential upside of 390.20%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sol-Gel Technologies
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Check-Cap
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Sol-Gel Technologies' average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company Overall Sentiment
Sol-Gel Technologies Neutral
Check-Cap Neutral

Summary

Sol-Gel Technologies beats Check-Cap on 8 of the 13 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLGL vs. The Competition

MetricSol-Gel TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$23.42M$3.87B$5.55B$9.41B
Dividend YieldN/A1.27%3.75%4.03%
P/E Ratio-1.747.3228.0119.82
Price / Sales1.9711.70432.6698.27
Price / CashN/A6.3636.1658.27
Price / Book0.792.708.125.65
Net Income-$10.58M-$109.62M$3.25B$257.91M
7 Day Performance0.25%-3.48%1.68%3.38%
1 Month Performance13.33%5.62%7.30%11.11%
1 Year Performance-0.61%2.84%32.89%18.99%

Sol-Gel Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLGL
Sol-Gel Technologies
3.3378 of 5 stars
$8.16
-3.0%
$40.00
+390.2%
-5.5%$23.42M$11.54M-1.7450Positive News
Gap Down
CHEK
Check-Cap
N/A$0.81
+10.1%
N/A-62.7%$4.33MN/A-0.2780Positive News
DRCT
Direct Digital
3.0685 of 5 stars
$0.64
+2.7%
$6.00
+837.5%
-86.9%$11.79M$48.17M-0.3660News Coverage
Gap Up
EXOZ
eXoZymes
N/A$10.18
+2.7%
N/AN/A$82.93M$70K0.0029Positive News
Gap Up
CABA
Cabaletta Bio
2.8271 of 5 stars
$1.49
-8.6%
$14.43
+868.4%
-76.3%$82.71MN/A-0.5950
JMAC
Maxpro Capital Acquisition
N/A$6.14
-6.4%
N/A+2,730.2%$82.45MN/A0.002,021
IGMS
IGM Biosciences
4.6055 of 5 stars
$1.35
-0.7%
$5.50
+307.4%
-88.0%$81.29M$2.68M-0.41190Positive News
PLRX
Pliant Therapeutics
4.0901 of 5 stars
$1.18
-6.3%
$13.31
+1,028.2%
-88.5%$77.35M$1.58M-0.3390
ZURA
Zura Bio
3.0424 of 5 stars
$1.10
-2.7%
$14.33
+1,203.0%
-45.3%$77.26MN/A-1.573News Coverage
Gap Up
EPIX
ESSA Pharma
1.0048 of 5 stars
$1.70
-2.3%
$2.00
+17.6%
-65.1%$77.24MN/A-2.7050
QNCX
Quince Therapeutics
3.1257 of 5 stars
$1.63
+1.2%
$8.00
+390.8%
+152.0%$73.21MN/A-1.1760News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SLGL) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners